ChinaDrugStatus

Ivosidenib

艾伏尼布
Brand: Tibsovo / 拓舒沃·Oncology / Hematology·Last verified 2026-11-20

IDH1 inhibitor whose 2026 NRDL payment scope expands beyond relapsed/refractory AML to cover first-line IDH1-mutated AML combined with azacitidine.

China Approval (NMPA)

Pending Verification

Reimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.

Verify directly on NMPA Portal ↗

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Edition Entry
Negotiated #298 · Class B
Agreement Period
2027-01-01 to 2027-12-31
Payment Standard
* Confidential (marked with asterisk in NHSA PDF)
2026 Payment Scope
Expanded to 2 indications: (1) Adult r/r IDH1-mutated AML; (2) First-line newly diagnosed IDH1-mutated AML in combination with azacitidine for patients aged ≥75 or ineligible for intensive induction chemotherapy.
限:1.携带易感异柠檬酸脱氢酶-1(IDH1)突变的复发性或难治性急性髓系白血病(AML)成人患者;2.联合阿扎胞苷用于携带易感异柠檬酸脱氢酶-1(IDH1)突变,因合并症无法使用强诱导化疗或者年龄≥75岁的新诊断急性髓系白血病(AML)患者。

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

2025 vs 2026 NRDL Payment Scope Comparison

2025 NRDL · #258NHSA · PDF p.164

Restricted to adults with relapsed or refractory AML with a susceptible IDH1 mutation.

限诊断为携带易感异柠檬酸脱氢酶-1(IDH1)突变的复发性或难治性急性髓系白血病(AML)成人患者。

2026 NRDL · #298NHSA · PDF p.149

Expanded to 2 indications: (1) Adult r/r IDH1-mutated AML; (2) First-line newly diagnosed IDH1-mutated AML in combination with azacitidine for patients aged ≥75 or ineligible for intensive induction chemotherapy.

限:1.携带易感异柠檬酸脱氢酶-1(IDH1)突变的复发性或难治性急性髓系白血病(AML)成人患者;2.联合阿扎胞苷用于携带易感异柠檬酸脱氢酶-1(IDH1)突变,因合并症无法使用强诱导化疗或者年龄≥75岁的新诊断急性髓系白血病(AML)患者。

Approved Products, Dosage Forms & Approval Numbers

0 verified NMPA records
Individual NMPA approval numbers (国药准字) and dosage strength rows have not yet been manually backfilled for this drug in our launch sample. Check the NMPA Drug Database Portal ↗ or request priority backfill.

Change Timeline

  1. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Payment Scope Updated

    Expanded beyond r/r IDH1-mutated AML in 2025 (#258) to add first-line newly diagnosed IDH1-mutated AML combined with azacitidine (age ≥75 or intensive-chemo ineligible) in 2026 (#298).

    Chinese original: 支付范围新增联用阿扎胞苷一线治疗≥75岁或不耐受强诱导化疗的新诊断IDH1突变AML患者(原2025版仅限复发/难治AML)。

    NHSA · PDF p.149Verified 2026-11-20

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

艾伏尼布片dosage name(NHSA)
Tibsovobrand en(WHO)
拓舒沃brand zh(NMPA)

Primary Sources for This Record